Exploring the potential of Regulus Therapeutics’ RNA-Targeted Drug RGLS8429 in autosomal dominant polycystic kidney disease (ADPKD)

Executed on:May 15, 2025 1:00 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Baylor/Texas A&MClinical Assistant Professor of Medicine at Texas A&M University,  Staff Physician at the Baylor Regional Transplant Institute, and partner at Dallas Nephrology Associates
Manages 75 patients a week with kidney disease with a focus on chronic kidney disease, end stage renal disease, transplantation, and dialysis.
Active in clinical research and is published in international journals in both nephrology and transplantation. 

Interview Goal

On this call, we will discuss Regulus Therapeutics’ strategic vision for RGLS8429, including its differentiation within the ADPKD treatment landscape, the implications of recent clinical data, and next steps toward commercialization.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.